On this page
Quick Reference
Overview and Recommendations
Background
- •Radiation therapy (RT) for gastric cancer targets locoregional control, addressing the dominant failure pattern after limited nodal dissection. The landmark INT-0116 trial (1998) established postoperative chemoradiotherapy (45 Gy with concurrent fluorouracil and leucovorin) as a standard after R0 resection with D0/D1 lymphadenectomy, reducing locoregional relapse and improving overall survival (HR 1.32).
- •The benefit of adjuvant RT is context-dependent: after adequate D2 gastrectomy, the addition of radiotherapy to modern chemotherapy (e.g., SOX) does not improve disease-free survival (ARTIST 2). Subgroup analyses suggest possible benefit in node-positive, intestinal-type tumors, but routine use is not recommended.
- •For patients with locally advanced, unresectable gastric cancer, definitive chemoradiotherapy (45-50.4 Gy) provides durable disease control, with clinical complete response rates of 12-45% and median overall survival of 11-26 months. Palliative RT (30 Gy/10 fx) effectively controls bleeding (60-90%), pain (45-100%), and obstruction (53-100%) with <5% grade 3 GI toxicity.
- •Preoperative chemoradiotherapy increases pathological complete response (pCR) rates (17% vs 8% in TOPGEAR) but does not improve overall survival compared to perioperative chemotherapy alone. It is conditionally recommended for borderline resectable tumors or patients who cannot tolerate perioperative chemotherapy.
- •Brachytherapy (interstitial HDR or permanent 125I seeds) offers a minimally invasive option for limited-volume metastases (<3 cm, PTV <45 cm³) or locoregional recurrence after gastrectomy, achieving local control of 89% and 50% complete response, respectively, with low toxicity.
- •The paradigm shift from 3D-CRT to IMRT/VMAT, combined with breath-hold techniques and daily IGRT, has improved target coverage and reduced toxicity to kidneys, liver, and bowel. Renal function is a key concern, with left kidney dose constraints (mean ≤13 Gy, V20 ≤13%) critical to prevent functional impairment.
Evaluation
- •Suspect the need for gastric cancer RT in any patient with resected stage IB-III disease after D0/D1 lymphadenectomy, unresectable local disease, or symptomatic bleeding/pain/obstruction from advanced disease.
- •Review the operative report to determine the extent of lymph node dissection (D0/D1 vs D2) and margin status (R0/R1/R2), this is the single most important factor guiding RT indication.
- •Assess patient fitness for concurrent chemotherapy: ECOG performance status 0-2, adequate renal function (eGFR ≥30 mL/min), hepatic function, and marrow reserve (ANC ≥1.5, platelets ≥100).
- •Obtain a baseline contrast-enhanced CT of the chest, abdomen, and pelvis for staging and treatment planning. PET/CT may be considered for detection of occult metastases, especially in the preoperative setting.
- •For adjuvant RT after D2 dissection, identify high-risk features: pT3-4, lymph node ratio >25%, or extraperigastric nodal involvement. A nomogram (AUC 0.79) can predict locoregional failure risk and guide patient selection.
- •For definitive RT, perform endoscopic ultrasound (EUS) for T and N staging, and rule out distant metastases with imaging. Consider diagnostic laparoscopy to exclude peritoneal dissemination before high-dose RT.
- •For palliative RT, document the target symptom (bleeding, pain, obstruction) and its severity. For bleeding, confirm active bleeding source via endoscopy and consider prior embolization if RT is not immediately available.
- •Assess prior radiation exposure: if the patient has received previous abdominal RT, obtain treatment records and calculate cumulative dose to OARs, especially kidneys, spinal cord, and bowel.
- •Evaluate for contraindications: active inflammatory bowel disease, pregnancy, prior radiation to the same field exceeding tolerance, or inability to tolerate immobilization (e.g., breath-hold).
- •Obtain a 4D CT simulation with the patient in supine position, arms up, with a custom immobilization device. Use oral contrast to delineate the stomach body and tumor bed. Consider breath-hold planning if respiratory motion >1 cm in the SI direction.
Management
- •For adjuvant RT after D0/D1 R0 resection: prescribe 45 Gy in 25 fractions (1.8 Gy/fx) to the tumor bed, anastomosis, duodenal stump, and regional lymph nodes (perigastric stations 1-6, celiac 9, splenic 10-11, hepatoduodenal 12, pancreaticoduodenal 13, para-aortic 16).
- •Deliver concurrent chemotherapy: fluorouracil 425 mg/m²/day IV bolus on days 1-5 and leucovorin 20 mg/m²/day IV bolus on days 1-5, repeated at weeks 1, 5, and 9 (INT-0116 regimen). Alternatively, capecitabine 825 mg/m² PO BID on days of RT (ARTIST regimen).
- •After D2 R0 resection, do not routinely add RT to adjuvant chemotherapy. For patients with high-risk features (pT3-4, N2+, extraperigastric LN), consider a shared decision-making discussion; if RT is offered, target the para-aortic basin (stations 16a/16b) and omit perigastric stations 1-6 and splenic hilum.
- •For unresectable nonmetastatic disease: prescribe 50.4 Gy in 28 fractions (1.8 Gy/fx) with concurrent fluoropyrimidine (e.g., capecitabine 825 mg/m² BID) or FOLFOX. Consider induction chemotherapy (2 cycles of SOX or FOLFOX) before CRT.
- •For palliative RT for bleeding: prescribe 30 Gy in 10 fractions (3 Gy/fx). Symptom relief typically occurs within 2-10 days. For pain or obstruction, the same regimen is effective; for obstruction, consider a higher dose (39 Gy in 13 fx or 40 Gy in 20 fx) if tolerance permits.
- •Use IMRT or VMAT preferentially to reduce dose to kidneys, liver, and bowel. Key OAR constraints: liver mean ≤16 Gy, V30 ≤21%; right kidney mean ≤9 Gy, V20 ≤9%; left kidney mean ≤13 Gy, V20 ≤13%; heart V40 ≤17%; bowel mean ≤11 Gy, V40 ≤6%; spinal cord max ≤33 Gy.
- •Implement respiratory motion management: use 4D CT simulation to define the ITV. If breath-hold is feasible, use deep inspiration breath-hold (DIBH) to reduce SI motion to ~2 mm, allowing margin reduction and potential dose escalation to 54 Gy.
- •For patients with preexisting nephropathy (eGFR <60 mL/min), prioritize IMRT/VMAT and consider referral to a center with proton therapy to further reduce renal dose.
- •Monitor during treatment: weekly CBC, CMP, and symptom assessment. Grade 3 GI toxicity (nausea, vomiting, diarrhea) occurs in 0-31% of definitive cases; manage with antiemetics (ondansetron 8 mg PO TID, prochlorperazine 10 mg PO QID), loperamide, and IV fluids as needed.
- •Do not use multiagent concurrent chemotherapy (e.g., ECF), CALGB 80101 showed no survival benefit over single-agent fluoropyrimidine.
- •Do not add postoperative RT after preoperative chemotherapy and D2 surgery (CRITICS trial showed harm, HR 1.62).
- •For brachytherapy candidates: select patients with ≤5 metastases, each <3 cm, PTV <45 cm³, and good performance status. For liver metastases, use image-guided HDR interstitial brachytherapy (single fraction, 15-20 Gy). For locoregional recurrence, use CT-guided 125I seed implantation (100-160 Gy minimal peripheral dose).
- •After RT, monitor for late toxicity: anastomotic stricture (5.9%), dysphagia (28.3% with right esophagojejunostomy, 12.5% with left), and pancreatic fistula. Refer to surgical oncology for management of strictures (endoscopic dilation) and nutritional support if needed.
- •Refer to palliative care early for symptom management and advanced care planning, especially for patients with inoperable disease. Early integration reduces emergency visits and hospitalizations.
- •Discharge criteria from RT: completion of prescribed course, stable vital signs, adequate oral intake, controlled pain, and no evidence of acute grade ≥3 toxicity. Follow up in 4-6 weeks with imaging and symptom assessment.
Board Review — High Yield
- •INT-0116, Landmark trial establishing adjuvant chemoradiotherapy (45 Gy + FU/leucovorin) after D0/D1 R0 resection for T3-4 or N+ gastric cancer; HR for OS 1.32, HR for RFS 1.51.
- •ARTIST 2, After D2 resection, adding RT to SOX does not improve 3-year DFS compared to SOX alone (72.8% vs 74.3%; HR 0.971); modern chemotherapy alone is sufficient.
- •CRITICS trial, After preoperative chemotherapy and D2 surgery, postoperative chemoradiotherapy worsened OS compared to chemotherapy alone (per-protocol 5-year OS 45.5% vs 57.9%; HR 1.62).
- •TOPGEAR, Preoperative CRT (45 Gy) increases pCR (17% vs 8%) but does not improve OS over perioperative chemotherapy alone.
- •Palliative RT dose, 30 Gy in 10 fractions is the standard for bleeding, pain, and obstruction; response rates: bleeding 60-90%, pain 45-100%, obstruction 53-100%.
- •IMRT benefit, Meta-analysis shows IMRT improves 3-year local control over 3D-CRT with no significant difference in OS or toxicity.
- •Brachytherapy selection, Lesion size <3 cm and PTV <45 cm³ are critical predictors of complete response; HDR iBT for metastases, 125I seeds for locoregional recurrence.
- •Para-aortic station 16, Most common site of locoregional failure after D2 dissection; should be included in CTV for high-risk patients.
- •Left kidney dose, Mean ≤13 Gy, V20 ≤13% are critical constraints to prevent functional impairment; use IMRT or breath-hold to achieve.
- •CALGB 80101, Multiagent concurrent chemotherapy (ECF) does not improve survival over single-agent FU when combined with RT; use single-agent FU.
Deep Dive — Evidence Details
Indications by Stage
- ▸Adjuvant chemoradiotherapy after D2 gastrectomy does not improve survival; it is indicated only after suboptimal (D0/D1) nodal dissection or R1/R2 resection.
- ▸Preoperative chemoradiation increases pCR rate but does not improve overall survival compared with perioperative chemotherapy alone.
- ▸Definitive chemoradiation offers durable local control for inoperable nonmetastatic disease, and palliative RT provides high rates of symptom relief for bleeding, pain, and obstruction.
Radiation therapy for is indicated across the disease spectrum, from curative-intent adjuvant treatment to palliation of advanced disease. The appropriate indication depends on the surgical approach, nodal dissection extent, and patient fitness for multiagent chemotherapy.
Resectable Disease
Adjuvant chemoradiotherapy is indicated after suboptimal nodal dissection. The landmark INT-0116 trial established that for patients with T3-4 and/or node-positive gastric cancer after R0 resection with limited lymphadenectomy (54% had less than D1 dissection), postoperative chemoradiotherapy (45 Gy with concurrent fluorouracil and leucovorin) improved overall survival compared with observation alone (HR for OS 1.32, 95% CI 1.10-1.60) [2]A1b. This benefit was driven by a reduction in locoregional failure [2]A1b. However, this advantage does not extend to patients who receive adequate D2 lymphadenectomy. The ARTIST trial [5]A1b and its final analysis [3]A1b found no significant difference in disease-free survival between adjuvant chemotherapy alone and chemoradiotherapy after D2 (HR 0.740, 95% CI 0.520-1.050) [3]A1b. A recent Chinese phase III trial of S-1 plus (SOX) versus SOX plus radiotherapy (50.4 Gy) after D2 gastrectomy confirmed no improvement in 3-year DFS (70.5% vs 69.3%; HR 0.98, 95% CI 0.73-1.33) or OS [19]A1b. Therefore, adjuvant chemoradiation is not recommended after a D2, R0 resection [19]A1b.
For patients who receive preoperative chemotherapy, the addition of postoperative chemoradiotherapy does not improve survival. The CRITICS trial showed that after preoperative chemotherapy and surgery (with D1+ dissection in most), postoperative chemoradiotherapy did not improve OS compared with postoperative chemotherapy (median OS 37 vs 43 months; HR 1.01, 95% CI 0.84-1.22) [9]A1b. The per-protocol analysis actually favored chemotherapy alone, with 5-year OS of 57.9% versus 45.5% (adjusted HR 1.62, 95% CI 1.24-2.12; P=0.0004) [1]A1b.
Preoperative chemoradiation is conditionally recommended for borderline resectable tumors or when patients cannot tolerate perioperative chemotherapy. The TOPGEAR trial demonstrated that adding preoperative chemoradiotherapy (45 Gy) to perioperative chemotherapy did not improve OS (median 46 vs 49 months; HR 1.05, 95% CI 0.83-1.31) but did increase pathological complete response (pCR) rate (17% vs 8%) [11]B2b. A Chinese phase III trial similarly found no survival benefit for preoperative chemoradiotherapy over preoperative chemotherapy alone, though pCR was higher (12% vs 2.1%) [20]A1b. The ASTRO guideline recommends preoperative chemoradiation for patients who are not candidates for perioperative chemotherapy, particularly for gastroesophageal junction or upper/middle third gastric tumors [15]A1c.
Unresectable Nonmetastatic Disease
For patients with locally advanced, unresectable gastric cancer, definitive chemoradiotherapy can provide durable disease control. A systematic review of 10 studies (n=354) using doses of 45-50.4 Gy in 25-28 fractions reported median overall survival ranging from 11 to 26.4 months, with clinical complete response rates of 12%-45% [17]A1a. Grade 3 GI toxicity ranged from 0-31% and RT completion rates were 81-100% [17]A1a. The ASTRO guideline strongly recommends definitive chemoradiation with or without induction/consolidation chemotherapy for nonmetastatic patients who are inoperable or decline surgery [15]A1c.
Palliative Indications
Radiation therapy is highly effective for palliating symptoms of advanced gastric cancer. A systematic review of 21 high-dose palliative studies (n=955) reported bleeding response rates of 59.6%-90%, pain response rates of 45.5%-100%, and obstruction response rates of 52.9%-100%, with grade 3 GI toxicity <5% [17]A1a. The ASTRO guideline strongly recommends palliative RT for bleeding and pain, and conditionally for obstruction [15]A1c. Commonly used regimens include 30 Gy in 10 fractions, with symptom relief typically seen within days to 2 weeks [17]A1a.
Pearl: For patients with D2-resected gastric cancer, the addition of radiotherapy to adjuvant chemotherapy does not improve survival; its role is limited to cases of suboptimal nodal dissection (D0/D1) or R1/R2 resection, where it remains a conditionally recommended option.
| Trial | Population | Intervention | Key Finding | Implication for Indication |
|---|---|---|---|---|
| INT-0116 [2]A1b | R0, T3-4/N+, <D2 dissection | Postop CRT vs observation | OS HR 1.32 (95% CI 1.10-1.60) | Postop CRT indicated for <D2 |
| ARTIST [3]A1b[5]A1b | D2, R0, all stages | XP vs XPRT | DFS similar; subset benefit in node+ | Not routine after D2 |
| CRITICS [1]A1b[9]A1b | Preop chemo, D1+ dissection | Postop chemo vs CRT | OS HR 1.01 (95% CI 0.84-1.22) | No benefit for postop CRT after preop chemo |
| TOPGEAR [11]B2b | Resectable, perioperative chemo | Preop CRT + chemo vs chemo alone | OS HR 1.05 (95% CI 0.83-1.31) | Preop CRT not superior to chemo alone |
| Chinese D2 trial [19]A1b | D2, T4/N+, R0 | SOX vs SOX+RT (50.4 Gy) | 3y DFS 70.5% vs 69.3% (HR 0.98) | No benefit for adjuvant RT after D2 |
| Definitive RT [17]A1a | Inoperable, nonmetastatic | 45-50.4 Gy/25-28# with chemo | mOS 11-26.4 mo, cCR 12-45% | Definitive CRT offers durable control |
| Palliative RT [17]A1a | Advanced/metastatic | 30 Gy/10# (most common) | Bleeding RR 60-90%, pain RR 46-100% | Effective palliation for bleeding, pain, obstruction |
External Beam Radiotherapy (EBRT)
- ▸The standard adjuvant dose is 45 Gy in 25 fractions; 50.4 Gy in 28 fractions is used in phase II studies and for definitive-intent RT.
- ▸After D2 dissection, the target volume can omit perigastric stations 1-6 and splenic stations 10-11, but must include the para-aortic basin (stations 16a/b), the most common site of recurrence.
- ▸IMRT improves local control over 3D-CRT without increasing toxicity; combining breath-hold and IGRT allows margin reduction and potential dose escalation to 54 Gy.
For patients meeting the indications outlined above, the technical delivery of must be tailored to the extent of surgery, the nodal basins at risk, and the surrounding normal tissues. The available evidence supports a consistent dose-fractionation framework, increasingly delivered with modern conformal techniques that reduce toxicity while maintaining target coverage.
Dose and Fractionation
The most widely studied dose regimen in the adjuvant setting is 45 Gy in 25 fractions of 1.8 Gy, delivered 5 days per week over 5 weeks [21]A1b[22]A1b[23]A1b[30]C4. This regimen was used in the landmark SWOG/INT-0116 trial and replicated in the ARTIST, NCC, and Chinese trials [22]A1b. The Chinese multicenter IMRT trial, which randomized 351 patients after D2 dissection, used this dose with concurrent /leucovorin and found a significant improvement in recurrence-free survival (median 36 vs 50 months; HR 1.35, 95% CI 1.03-1.78; P=0.029), though overall survival difference was not significant (48 vs 58 months; HR 1.24, 95% CI 0.94-1.65; P=0.122) [23]A1b. For patients with high-risk features (pN stage ≥ N2 and extraperigastric lymph node metastasis), the 3-year DFS improved from 53.0% with chemotherapy alone to 71.0% with adjuvant CRT (HR 0.53, 95% CI 0.29-0.97; P<0.05); NNT = 6 to prevent one recurrence at 3 years [21]A1b.
A dose of 50.4 Gy in 28 fractions (1.8 Gy per fraction) has also been evaluated in phase II and phase I studies, both in the adjuvant setting with concurrent FOLFOX [29]B2b and in the definitive setting for inoperable patients [28]B2b[38]C4. In a phase II study of 36 patients with inoperable nonmetastatic , 50.4 Gy with concurrent yielded a clinical complete response rate of 36% (95% CI 19%-53%) and median overall survival of 25.8 months (95% CI 7.1-44.5 months) [28]B2b. For definitive-intent RT, the systematic review of 10 studies reported doses of 45-50.4 Gy in 25-28 fractions (BED10 >45 Gy), with median overall survival ranging from 11 to 26.4 months [17]A1a.
Target Volume Delineation
Target volume definition depends critically on the extent of lymph node dissection. In the SWOG/INT-0116 trial, where most patients underwent D0/D1 dissection, the radiation field encompassed the tumor bed, anastomosis, duodenal stump, and regional lymph nodes (perigastric stations 1-6, celiac 9, splenic 10-11, hepatoduodenal 12, pancreaticoduodenal 13, and para-aortic 16) [22]A1b. After D2 dissection, the pattern of recurrence shifts, and the target volume can be modified. The ARTIST trial excluded perigastric stations 1-6, the splenic hilum (station 10), and the proximal splenic artery (station 11), based on failure pattern analysis after D2 dissection [22]A1b. The most common sites of regional recurrence after D2 dissection are the para-aortic nodes (stations 16a/16b), followed by hepatoduodenal (station 12), superior mesenteric (station 14), retropancreatic (station 13), and celiac (station 9) nodes [22]A1b. The present evidence supports that perigastric stations 1-6 and splenic stations 10-11 may be safely omitted after adequate D2 dissection, while the para-aortic basin (stations 16a/16b) should be routinely included [22]A1b.
Treatment Planning and Delivery Techniques
Modern EBRT for gastric cancer increasingly uses intensity-modulated radiotherapy (IMRT) rather than three-dimensional conformal radiotherapy ( ). A meta-analysis of 9 controlled clinical studies including 516 patients found that IMRT was associated with a significantly higher 3-year local control rate compared with 3D-CRT, with no significant difference in 3-year OS, 3-year DFS, or grade 2-4 toxicity [36]B2a. IMRT provides superior dose conformity and allows better sparing of the kidneys, liver, and bowel [25]D5. Single-arc volumetric-modulated arc therapy (sVMAT) achieves similar dose distribution to IMRT, with improved sparing of the left kidney and liver compared with 3D-CRT, though few dosimetric advantages over IMRT [33]A1b. Some authors have noted that IMRT confers only a marginal benefit over 3D-CRT in the adjuvant setting and should be reserved for patients with preexisting nephropathy or other risk factors for kidney disease [32]B2b. In the adjuvant setting, image-guided radiotherapy (IGRT) with daily cone-beam CT or orthogonal kV imaging is recommended to account for interfractional variations in stomach bed position and bowel gas [25]D5.
Organ-at-Risk Constraints and Motion Management
Critical organs at risk during gastric EBRT include the kidneys, liver, spinal cord, heart, and bowel. The following dose constraints, derived from a prospective feasibility study of IMRT, represent achievable planning goals [30]C4:
| Organ | Constraint |
|---|---|
| Liver | Mean dose ≤ 16 Gy; V30 ≤ 21% |
| Right kidney | Mean dose ≤ 9 Gy; V20 ≤ 9% |
| Left kidney | Mean dose ≤ 13 Gy; V20 ≤ 13% |
| Heart | Median dose ≤ 15 Gy; V40 ≤ 17% |
| Bowel | Mean dose ≤ 11 Gy; V40 ≤ 6% |
| Spinal cord | Maximum dose ≤ 33 Gy |
Renal function is a particular concern because the left kidney is often in close proximity to the target volume. Functional MRI studies have shown that renal subvolumes receiving ≥ 35 Gy in 1.5-2 Gy fractions develop measurable impairment of sodium handling, whereas doses below 20-25 Gy in 1 Gy fractions do not produce detectable functional or morphological changes [34]B2b.
Respiratory motion significantly affects gastric cancer RT. The mean target motion during free breathing is 11.1 mm in the superior-inferior direction, 1.9 mm in the left-right direction, and 5.5 mm in the anterior-posterior direction [31]B2b. Incorporating breath-hold (BH) techniques reduces SI motion to 2.2 mm, and combining BH with online IGRT allows margin reduction and potential dose escalation to 54 Gy without increasing toxicity [31]B2b. Four-dimensional CT (4D CT) simulation is recommended to characterize the internal target volume (ITV) and inform margin selection [25]D5.
Pearl: After D2 dissection, the para-aortic nodal basin (stations 16a/b) is the most common site of locoregional failure and should be included in the target volume, while perigastric stations 1-6 and splenic stations 10-11 may be safely omitted to reduce gastrointestinal toxicity [22]A1b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Is IMRT clearly superior to 3D-CRT for adjuvant gastric RT? | IMRT improves local control without increasing toxicity [36]B2a. | IMRT confers only marginal benefit and should be reserved for patients with nephropathy risk [32]B2b. | Moderate | Most centers adopt IMRT/ ; 3D-CRT remains acceptable where IMRT is not available, but the target volume and OAR constraints must be carefully respected. |
| Should the para-aortic region (station 16) be routinely included after D2 dissection? | Yes, it is the most common site of nodal recurrence [22]A1b. | The SWOG/INT-0116 field included it, but some centers omit it to reduce renal and bowel dose [22]A1b. | Strong | Inclusion is recommended for high-risk patients; omission may be considered in early-stage patients to reduce toxicity, but supporting data are limited. |
Brachytherapy
- ▸Brachytherapy is a salvage option for inoperable locoregional recurrence or oligometastatic gastric cancer, with local control rates of 89% for metastases and 50% complete response for recurrences.
- ▸Lesion size <3 cm and planning target volume <45 cm³ predict better outcomes after permanent seed implantation.
- ▸The procedure is well tolerated, with low rates of grade ≥3 toxicity when performed with image guidance.
Following , which addresses the primary tumor and regional lymphatics, offers a complementary strategy for localized deposits that are not amenable to further without exceeding normal tissue tolerance. In , brachytherapy is primarily used as a salvage or palliative treatment for metastatic disease or locoregional recurrence, where surgical resection is often not feasible.
Image-Guided Interstitial Brachytherapy for Metastatic Disease
For patients with hepatic, lymphatic, or pancreatic metastases from , image-guided high-dose-rate interstitial brachytherapy (iBT) provides a minimally invasive option. Omari et al. reported a retrospective series of 12 patients with 36 metastases (29 liver, 2 pancreatic, 5 lymph node) treated with a single-fraction iridium-192 source after prior palliative chemotherapy. The procedure achieved local tumor control in 32 of 36 treated metastases (89%). Four lesions recurred after a median of 7 months. The median progression-free survival was 6.6 months (range, 1.8-46.8 months), and median overall survival was 11.4 months (range, 5-47 months). One major complication occurred, a grade 3 hepatic hematoma and abscess requiring transcutaneous drainage. No treatment-related deaths were reported [43]C4.
CT-Guided Permanent Brachytherapy for Locoregional Recurrence
Locoregional recurrence after is a common pattern of failure, often inoperable. Shi et al. evaluated CT-guided permanent brachytherapy using 125I seed implantation in 28 patients with limited locoregional recurrence. Between 15 and 75 seeds were implanted per patient to deliver a minimal peripheral dose of 100-160 Gy. Early dosimetry showed a median V100 of 95.8% and D90 of 105.2% of the prescription dose. At 2 months, complete response was observed in 50.0% of patients, partial response in 28.6%, and progressive disease in 21.4%. Median survival was 22.0 ± 5.2 months, with 1-, 2-, and 3-year survival rates of 89 ± 6%, 52 ± 10%, and 11 ± 7%, respectively. No serious complications occurred [47]D5.
Predictors of Response
Tumor size and target volume are key determinants of outcome. In the same study, patients with tumors <3 cm had a significantly higher complete response rate (66.7%) compared with those with larger tumors (30.8%). A planning target volume (PTV) smaller than 45 cm³ was also significantly correlated with complete tumor eradication (P = 0.020). These findings suggest that patient selection for brachytherapy should favor small, well-defined recurrences [47]D5.
Radiobiological Rationale
Preclinical evidence supports the efficacy of continuous low-energy irradiation from 125I seeds. In a murine xenograft model of human gastric cancer, 125I seed irradiation (0.6 mCi) induced significant apoptosis and G2/M phase arrest. Treated tumors showed reduced expression of NF-κB and VEGF at both mRNA and protein levels, suggesting that brachytherapy suppresses angiogenesis and pro-survival signaling pathways, contributing to growth inhibition and volume reduction [48]D5.
Safety and Feasibility
Both HDR interstitial brachytherapy and permanent seed implantation are well tolerated in appropriately selected patients. The reported rates of severe adverse events (CTCAE grade ≥3) are low. In the iBT series, one major complication occurred (2.8% of treated metastases). In the permanent seed series, no serious complications were reported. Radiation-induced toxicity to adjacent organs is minimized by precise image guidance and careful dosimetric planning [43]C4[47]D5.
Patient Selection and Clinical Considerations
Brachytherapy should be considered for patients with limited-volume metastatic or recurrent gastric cancer who have progressed on systemic therapy or are not candidates for further surgery. Optimal candidates have:
- Solitary or oligometastatic disease (≤5 lesions)
- Lesion size <3 cm (or PTV <45 cm³)
- Favorable performance status
- Symptomatic or progressive disease amenable to focal treatment
Lesions near critical structures (e.g., major bile ducts, bowel loops) require careful CT or MRI-based planning to avoid excessive exposure. The procedure is typically performed under conscious sedation or local anesthesia, with post-procedure imaging for verification.
Pearl: For selected patients with limited locoregional recurrence or oligometastases from gastric cancer, brachytherapy achieves high local control (89% for metastases, 50% complete response for recurrences) with minimal toxicity, but lesion size <3 cm and PTV <45 cm³ are critical predictors of success [43]C4[47]D5.
| Indication | Technique | Patients (n) | Local Control | Median Survival | Reference |
|---|---|---|---|---|---|
| Hepatic, lymphatic, pancreatic metastases | HDR iridium-192 interstitial BT | 12 (36 lesions) | 89% (32/36) | OS 11.4 mo, PFS 6.6 mo | [43]C4 |
| Locoregional recurrence | CT-guided 125I seed permanent BT | 28 | CR 50%, PR 28.6% | 22.0 mo (1-yr 89%, 2-yr 52%) | [47]D5 |
Concurrent Chemoradiation
- ▸Adjuvant concurrent chemoradiation with 45 Gy and fluorouracil-based chemotherapy improves overall and relapse-free survival after D0/D1 resection (INT-0116).
- ▸After D2 dissection, the benefit of adding radiotherapy is limited to node-positive and intestinal-type gastric cancer (ARTIST); chemotherapy alone may be superior (CRITICS).
- ▸Multiagent concurrent chemotherapy (ECF) does not improve survival over single-agent fluoropyrimidine when combined with radiation (CALGB 80101).
Following the limited applicability of , with concurrent chemotherapy has been the cornerstone of adjuvant treatment for high-risk , based on landmark trials. The concurrent agent acts as a radiosensitizer, enhancing locoregional control without substantially increasing toxicity when delivered at standard doses. The evidence base rests on four key randomized trials, each informing the role of concurrent chemoradiation in different surgical contexts.
INT-0116: The Foundational Trial
The Intergroup 0116 trial established adjuvant chemoradiation as a standard after suboptimal (D0/D1) lymphadenectomy. Patients with stage IB-IV (M0) gastric cancer received 45 Gy in 25 fractions with concurrent bolus fluorouracil and leucovorin, followed by two additional cycles of chemotherapy. With a median follow-up exceeding 10 years, the hazard ratio for overall survival was 1.32 (95% CI 1.10-1.60) favoring the treatment arm, and the hazard ratio for relapse-free survival was 1.51 (95% CI 1.25-1.83; P < 0.001) [2]A1b. Locoregional relapse was substantially reduced, confirming that concurrent chemoradiation addresses the dominant failure pattern after limited nodal dissection.
ARTIST: The D2-Dissection Context
The ARTIST trial tested whether adding radiotherapy to adjuvant chemotherapy improved outcomes after D2 resection. Patients received either six cycles of plus (XP) or two cycles of XP followed by concurrent chemoradiation (capecitabine-based) and then two additional XP cycles. With 7 years of follow-up, disease-free survival was similar between arms (HR 0.740; 95% CI 0.520-1.050) [3]A1b. However, prespecified subset analyses showed a significant DFS benefit from chemoradiation in patients with node-positive disease and those with intestinal-type histology (interaction for DFS by Lauren classification) [3]A1b. This suggests that after adequate D2 dissection, concurrent chemoradiation may benefit specific subgroups rather than all patients.
CALGB 80101 and CRITICS: Refining the Chemotherapy Backbone
CALGB 80101 compared postoperative FU plus leucovorin with , cisplatin, and infusional fluorouracil (ECF), both given before and after concurrent FU-based radiotherapy. Five-year overall survival was 44% in both arms (HR 0.98; 95% CI 0.78-1.24), demonstrating that a multiagent regimen does not improve outcomes over single-agent fluoropyrimidine when combined with radiation [4]A1b. The CRITICS trial, which randomized patients to postoperative chemotherapy alone or chemoradiation after preoperative chemotherapy and D2 surgery, reported a per-protocol 5-year overall survival of 57.9% with chemotherapy alone versus 45.5% with chemoradiation (adjusted HR 1.62; 95% CI 1.24-2.12; P = 0.0004) [1]A1b. This finding challenges the routine use of concurrent chemoradiation after optimal D2 dissection and supports chemotherapy alone in that setting.
Practical Considerations
Concurrent chemotherapy is typically a fluoropyrimidine (intravenous fluorouracil or oral capecitabine), with or without leucovorin. The radiation dose is 45 Gy in 25 fractions to the tumor bed and regional lymphatics, as used in INT-0116 [2]A1b. The choice of concurrent agent and the decision to add radiotherapy depend on the quality of surgery (D0/D1 vs D2), nodal status, and histologic subtype. The next section addresses the broader spectrum of adjuvant and palliative radiotherapy indications.
Pearl: Multiagent concurrent chemotherapy (ECF) does not improve survival over single-agent fluoropyrimidine when combined with radiation (CALGB 80101).
| Trial | Surgery | Arms | RT Dose | Key Result |
|---|---|---|---|---|
| INT-0116 [2]A1b | D0/D1 | Observation vs FU/LV + 45 Gy → FU/LV | 45 Gy/25 fx | HR for OS 1.32 (95% CI 1.10-1.60); HR for RFS 1.51 (95% CI 1.25-1.83) |
| ARTIST [3]A1b | D2 | XP ×6 vs XP ×2 → XPRT → XP ×2 | 45 Gy/25 fx (capecitabine concurrent) | DFS HR 0.740 (95% CI 0.520-1.050); benefit in node-positive and intestinal-type |
| CALGB 80101 [4]A1b | D0/D1/D2 | FU/LV + 45 Gy vs ECF + 45 Gy | 45 Gy/25 fx (FU concurrent) | 5-yr OS 44% both arms; HR 0.98 (95% CI 0.78-1.24) |
| CRITICS [1]A1b | D2 | Post-op CT vs post-op CRT (after pre-op CT) | 45 Gy/25 fx (capecitabine or FU concurrent) | 5-yr OS 57.9% CT vs 45.5% CRT; adjusted HR 1.62 (95% CI 1.24-2.12) |
Adjuvant and Palliative RT
- ▸Adjuvant chemoradiation is indicated after D1 lymphadenectomy but not after D2, based on local recurrence reduction from 8% to 2% at 2 years [69].
- ▸Palliative RT (most commonly 30 Gy in 10 fractions) provides effective symptom control for bleeding, pain, and obstruction, with low toxicity [17].
Following the concurrent chemoradiation strategies discussed above, the role of radiation therapy extends beyond the curative setting to both adjuvant and palliative contexts.
Adjuvant Radiation Therapy
Adjuvant chemoradiation is recommended for patients with stage IB-III who have not received neoadjuvant therapy, particularly after limited (D1) lymphadenectomy [68]D5. The landmark Intergroup 0116 (INT-0116) trial established that postoperative chemoradiation improves disease-free and overall survival in this population [74]D5. A meta-analysis of 11 randomized controlled trials including 4606 patients confirmed a significant survival benefit for any postoperative adjuvant therapy (HR 0.78; 95% CI 0.72-0.84; NNT = 14 to prevent one death, calculated from reported HR and baseline survival) [73]A1a. The benefit was most pronounced when chemotherapy was combined with immunotherapy or radiotherapy (HR 0.72; 95% CI 0.61-0.85) [73]A1a.
The impact of adjuvant RT depends critically on the extent of surgery. A retrospective comparison of two phase I/II chemoradiation studies with the Dutch Group Trial found that after D1 dissection, postoperative chemoradiation reduced the 2-year local recurrence rate from 8% to 2% (P = 0.001) [69]C4. After D2 dissection, no significant difference in local recurrence was observed [69]C4. Adjuvant RT also improved survival after microscopically irradical (R1) resection [69]C4.
A recurrence pattern analysis of 1169 patients who underwent D2 surgery identified independent risk factors for locoregional failure: pathologic T category 3-4 (vs 1-2) and lymph node ratio >25% (vs ≤25%) [81]B3b. A predictive nomogram incorporating these factors achieved an area under the curve of 0.79, suggesting a subpopulation that may derive particular benefit from adjuvant RT [81]B3b.
Palliative Radiation Therapy
For patients with inoperable gastric cancer, high-dose palliative RT provides effective symptom control. A systematic review of 21 studies (n = 955) reported bleeding response rates ranging from 59.6% to 90%, pain response rates from 45.5% to 100%, and obstruction response rates from 52.9% to 100% [17]A1a. The most commonly prescribed regimen was 30 Gy in 10 fractions [17]A1a. Grade 3 gastrointestinal toxicity was <5%, and RT completion rates ranged from 68% to 100% [17]A1a. A separate analysis of the National Cancer Database including >4700 patients with non-metastatic inoperable gastric cancer found a significant survival benefit when RT was added to chemotherapy [17]A1a.
Definitive-intent RT (45-50.4 Gy in 25-28 fractions) has been evaluated in 10 studies (n = 354) with median overall survival ranging from 11 to 26.4 months and clinical complete response rates of 12% to 45% [17]A1a. Grade 3 gastrointestinal toxicity ranged from 0% to 31% [17]A1a.
Palliative radiotherapy is one component of a broader symptom-directed approach for advanced gastric cancer, which also includes endoscopic stenting, arterial embolization, and palliative surgery [76]B2a. Early integration of specialist palliative care is associated with reduced emergency department visits and hospitalizations, and increased access to home-based care [80]B3b.
Pearl: Adjuvant chemoradiation should be considered after limited (D1) lymphadenectomy, where it reduces local recurrence from 8% to 2% [69]C4; for inoperable disease, high-dose palliative RT (≥30 Gy in 10 fractions) achieves bleeding control in 60-90% of cases with <5% grade 3 gastrointestinal toxicity [17]A1a.
Acute and Late Toxicity
- ▸Cardiotoxicity has a 4% incidence in gastric cancer patients receiving targeted agents, with the highest relative risk from vandetanib (RR 7.71) [83].
- ▸Anastomotic stricture occurs in 5.9% of DFT reconstructions; intracorporeal anastomosis reduces this risk (OR 2.00 for EOJ vs IOJ) [85,92].
- ▸Left esophagojejunostomy (LEJ) reduces dysphagia incidence from 28.3% to 12.5% compared to right-sided anastomosis, and is an independent protective factor (OR 0.248) [101].
The preceding discussion of adjuvant and palliative radiation underscores the importance of balancing efficacy with toxicity. While radiation-specific toxicity data for are not extensively reported in the available literature, the multimodality treatment approach, including concurrent chemoradiation and subsequent surgery, carries a well-defined risk profile that the clinician must anticipate and manage.
Cardiotoxicity of Targeted Agents
Cardiotoxicity is a serious concern with targeted agents used in concurrent chemoradiation. In a meta-analysis of 31 trials including 28,538 patients, the highest incidence of cardiotoxicity was observed in thyroid cancer (8%), followed by gastric cancer (4%) [83]B2a. The highest relative risk of high-grade events was seen with vandetanib (RR 7.71, 95% CI 1.04-56.99), followed by (RR 5.0) and aflibercept (RR 4.1) [83]B2a. Grouping by drug category, anti-VEGFR-TKIs carried the highest risk of high-grade cardiotoxicity (RR 5.62, 95% CI 1.49-21.24) [83]B2a. Frequent clinical monitoring is warranted when using these agents.
Postoperative Complications After Multimodality Therapy
Surgical resection following neoadjuvant chemoradiation or as part of definitive management carries a well-defined set of complications. The following table summarizes key complications, their frequencies, prevention strategies, and management approaches based on the available evidence.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Anastomotic leakage | 1.4% (DFT reconstruction) [85]A1a; 8.3% (surgery-first) [97]C4 | Duodenal stump reinforcement reduces DSF (OR 0.32, 95% CI 0.17-0.60) [91]B2a | Drainage, surgical repair, |
| Pancreatic fistula | 1.8% (DFT) [85]A1a; 0.17% lower with RATG vs LATG [86]A1a | Pancreas-contactless technique (0% vs 7.6%, p=0.006) [95]B3b; robotic in Type C LGV anatomy [94]C4 | Drainage, somatostatin analogs, nutritional support |
| Anastomotic stricture | 5.9% (DFT) [85]A1a; 3.7% EOJ vs 1.8% IOJ [92]B2a | Intracorporeal anastomosis (OR 2.00, 95% CI 1.16-3.44 for EOJ) [92]B2a; LEJ reduces dysphagia [101]C4 | Endoscopic dilation, surgical revision if severe |
| Cardiotoxicity (targeted agents) | 4% in gastric cancer [83]B2a | Baseline cardiac assessment, avoid high-risk agents in patients with pre-existing cardiac disease | Dose reduction, hold agent, cardiology consultation |
| Intra-abdominal abscess | 3.2% (contactless) vs 12.1% (contact) [95]B3b | Avoid pancreatic trauma, meticulous hemostasis | Drainage, culture-directed antibiotics |
| Dysphagia | 28.3% REJ vs 12.5% LEJ (p=0.035) [101]C4 | Left esophagojejunostomy (LEJ) technique (OR 0.248, 95% CI 0.906-1.518) [101]C4 | Dietary modification, prokinetics; surgical repositioning for volvulus |
Prevention and Management
Anastomotic complications are among the most feared toxicities. Duodenal stump reinforcement significantly reduces the risk of duodenal stump fistula (OR 0.32, 95% CI 0.17-0.60, p=0.0004) [91]B2a. The use of intracorporeal anastomosis during laparoscopic lowers the risk of anastomotic stricture (3.7% EOJ vs 1.8% IOJ; OR 2.00, 95% CI 1.16-3.44, p=0.01) [92]B2a. Left esophagojejunostomy (LEJ) is an independent protective factor against dysphagia (OR 0.248, p=0.022) and reduces the incidence from 28.3% to 12.5% [101]C4.
Pancreatic fistula can be minimized by avoiding direct pancreatic contact during suprapancreatic lymph node dissection; the pancreas-contactless technique reduced POPF from 7.6% to 0% (p=0.006) [95]B3b. Preoperative assessment of the left gastric vein (LGV) anatomy on CT can identify patients at highest risk (Type C: 17.9% vs 1.7%, p<0.001), and robotic gastrectomy may reduce this risk [94]C4.
Cardiotoxicity from targeted agents requires a proactive approach. Baseline cardiac evaluation and close monitoring of blood pressure, left ventricular function, and electrocardiogram during therapy are recommended. The risk is highest with anti-VEGFR-TKIs (RR 5.62) [83]B2a.
Pearl: Anastomotic stricture and dysphagia are common late complications after total gastrectomy; technique refinements such as left esophagojejunostomy (LEJ) and intracorporeal anastomosis significantly reduce these risks, and the benefit is seen in the first postoperative year [92]B2a[101]C4.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Anastomotic leakage | 1.4% (DFT) [85]A1a; 8.3% (surgery-first) [97]C4 | Duodenal stump reinforcement (OR 0.32) [91]B2a | Drainage, surgical repair, antibiotics |
| Pancreatic fistula | 1.8% (DFT) [85]A1a; 0% with contactless technique [95]B3b | Pancreas-contactless technique [95]B3b; robotic gastrectomy for Type C LGV [94]C4 | Drainage, somatostatin analogs, nutritional support |
| Anastomotic stricture | 5.9% (DFT) [85]A1a; 3.7% EOJ vs 1.8% IOJ [92]B2a | Intracorporeal anastomosis (OR 2.00 for EOJ) [92]B2a; LEJ reduces dysphagia [101]C4 | Endoscopic dilation, surgical revision if severe |
| Cardiotoxicity (targeted agents) | 4% in gastric cancer [83]B2a | Baseline cardiac assessment, avoid high-risk agents in susceptible patients | Dose reduction, hold agent, cardiology consultation |
| Intra-abdominal abscess | 3.2% (contactless) vs 12.1% (contact) [95]B3b | Avoid pancreatic trauma, meticulous hemostasis | Drainage, culture-directed antibiotics |
| Dysphagia | 28.3% REJ vs 12.5% LEJ [101]C4 | Left esophagojejunostomy (LEJ) technique (OR 0.248) [101]C4 | Dietary modification, prokinetics; surgical repositioning for volvulus |
Outcomes
- ▸Adjuvant chemoradiation (45 Gy) improves OS and RFS after R0 resection for T3+ or node-positive gastric cancer, with long-term benefit sustained beyond 10 years [2].
- ▸After D2 lymphadenectomy, adding radiotherapy to SOX chemotherapy does not further improve DFS, as shown in ARTIST 2 [110].
- ▸Nodal response to preoperative therapy is a critical prognostic factor; radiotherapy is associated with higher nodal response rates, and achieving nodal clearance correlates with improved survival [104].
After weighing the toxicity profile, the clinical value of radiotherapy is defined by its effect on survival and locoregional control. Landmark trials provide the evidence base.
Adjuvant Chemoradiation: INT-0116
With a median follow-up exceeding 10 years, the INT-0116 trial demonstrated a persistent benefit of postoperative chemoradiation (45 Gy to locoregional sites) after R0 resection for with primaries ≥T3 or node-positive disease. The hazard ratio for overall survival (OS) was 1.32 (95% CI 1.10-1.60), and the HR for relapse-free survival (RFS) was 1.51 (95% CI 1.25-1.83), both favoring the treatment arm [2]A1b. The reduction in locoregional relapse accounted for the majority of the relapse reduction. However, subset analysis showed minimal nonsignificant treatment effect in patients with diffuse histology [2]A1b. Second malignancies occurred in 21 patients in the radiotherapy arm versus 8 in the observation arm (P = 0.21), an acceptable trade-off for the survival gain.
Adjuvant Therapy After D2 Resection: ARTIST 2
In the ARTIST 2 trial, patients with D2-resected, stage II/III, node-positive gastric cancer were randomized to S-1 alone, SOX (S-1 plus ), or SOXRT (SOX plus 45 Gy chemoradiotherapy) [110]A1b. Estimated 3-year disease-free survival (DFS) rates were 64.8% with S-1, 74.3% with SOX, and 72.8% with SOXRT. DFS was significantly improved with SOX versus S-1 (HR 0.692; P = 0.042), and a trend was seen with SOXRT versus S-1 (HR 0.724; P = 0.074). Critically, no difference in DFS was found between SOX and SOXRT (HR 0.971; P = 0.879), indicating that the addition of radiotherapy to modern chemotherapy did not further reduce recurrence after D2 [110]A1b.
Preoperative Radiotherapy and Nodal Response
Sada et al. demonstrated that preoperative radiotherapy was associated with a higher nodal response rate compared with chemotherapy alone in clinically node-positive gastric cancer: 46.0% versus 29.1% in cardia and 43.8% versus 31.9% in noncardia [104]B3b. A nodal response with residual primary disease was significantly associated with improved survival (HR 0.54, 95% CI 0.44-0.65), whereas a primary tumor response with residual nodal disease conferred no survival benefit [104]B3b. This highlights nodal downstaging as a key prognostic endpoint.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Role of adjuvant RT after D2 resection | ARTIST 2: no benefit of adding RT to SOX [110]A1b | INT-0116: benefit of RT after limited lymphadenectomy [2]A1b | ARTIST 2 phase III; INT-0116 phase III but not mandatory D2 | For patients with D2 dissection, modern chemotherapy alone may suffice; RT should be reserved for high-risk features or inadequate lymphadenectomy. |
Pearl: Nodal response after preoperative therapy is a stronger prognostic marker than primary tumor response, and radiotherapy increases the likelihood of achieving nodal downstaging [104]B3b.
| Trial | Setting | Regimen | Outcome | Effect Size |
|---|---|---|---|---|
| ARTIST 2 [110]A1b | D2-resected, stage II/III, N+ | SOXRT vs SOX vs S-1 alone | 3-year DFS: SOX 74.3%, SOXRT 72.8%, S-1 64.8% | SOX vs S-1: HR 0.692 (P = 0.042); SOX vs SOXRT: HR 0.971 (P = 0.879) |
| Sada et al. [104]B3b | Preoperative cN+ | Chemo ± RT | Nodal response rate: 46% (RT) vs 29% (chemo) in cardia | Nodal response with residual primary: HR 0.54 (95% CI 0.44-0.65) |
Related Pages
Part of the Gastric Cancer family. Cross-cutting management is split across dedicated child pages:
- , diagnostic page (definition, epidemiology, staging, biomarkers, prognosis)
- Gastric Cancer Surgical Management , operations by stage, fertility-sparing options, sentinel node mapping, adjuvant triggers (Sedlis / Peters)
- , concurrent / adjuvant / metastatic chemotherapy, targeted therapy, immune checkpoint inhibitors
- Gastric Cancer Palliative Care , early integration, symptom management, palliative procedures, end-of-life care
- Gastric Cancer Surveillance and Follow-up , post-treatment surveillance schedule, late toxicity, survivorship, patient counselling
- Gastric Cancer Recurrent and Metastatic Disease , local-regional salvage, distant metastatic systemic therapy, oligometastatic disease
Pearl: Use these links to hop between management modalities; the parent Gastric Cancer page carries diagnosis + staging that informs every decision here.
References
- [1]
de Steur WO, van Amelsfoort RM, Hartgrink HH et al.. “Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33227408 ↗
L1RCTCited in: Indications by Stage, Concurrent Chemoradiation - [2]
Smalley SR, Benedetti JK, Haller DG et al.. “Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2012). PMID: 22585691 ↗
L1RCTCited in: Indications by Stage, Concurrent Chemoradiation, Outcomes - [3]
Park SH, Sohn TS, Lee J et al.. “Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 25559811 ↗
L1RCTCited in: Indications by Stage, Concurrent Chemoradiation - [4]
Fuchs CS, Niedzwiecki D, Mamon HJ et al.. “Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2017). PMID: 28976791 ↗
L1RCTCited in: Indications by Stage, Concurrent Chemoradiation - [5]
Lee J, Lim DH, Kim S et al.. “Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 22184384 ↗
L1RCTCited in: Indications by Stage - [6]
Sclafani F, Roy A, Cunningham D et al.. “HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 24146218 ↗
L2RCT_PHASE2Cited in: Indications by Stage, Concurrent Chemoradiation - [7]
Schwartz GK, Winter K, Minsky BD et al.. “Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2009). PMID: 19273696 ↗
L2RCT_PHASE2Cited in: Indications by Stage - [8]
Oehler C, Ciernik IF. “Radiation therapy and combined modality treatment of gastrointestinal carcinomas.” Cancer treatment reviews (2006). PMID: 16524667 ↗
L1RCTCited in: Indications by Stage, Adjuvant and Palliative RT - [9]
Cats A, Jansen EPM, van Grieken NCT et al.. “Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.” The Lancet. Oncology (2018). PMID: 29650363 ↗
L1RCTCited in: Indications by Stage - [10]
van Velzen MJM, Pape M, Sprangers MAG et al.. “Chemotherapy-Induced Peripheral Neuropathy in Patients With Gastroesophageal Cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2024). PMID: 38977016 ↗
L2PROSPECTIVE_COHORTCited in: Indications by Stage - [11]
Leong T, Smithers BM, Michael M et al.. “Preoperative Chemoradiotherapy for Resectable Gastric Cancer.” The New England journal of medicine (2024). PMID: 39282905 ↗
L2RCT_PHASE2Cited in: Indications by Stage - [12]
Gordon MA, Gundacker HM, Benedetti J et al.. “Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23524864 ↗
L2NON_RANDOMIZED_TRIALCited in: Indications by Stage - [13]
Vitolo U, Chiappella A, Ferreri AJ et al.. “First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21646602 ↗
L2NON_RANDOMIZED_TRIALCited in: Indications by Stage - [14]
Ajani JA, Winter K, Okawara GS et al.. “Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2006). PMID: 16921048 ↗
L2NON_RANDOMIZED_TRIALCited in: Indications by Stage, Adjuvant and Palliative RT - [15]
Anker CJ, Arshad J, Cellini F et al.. “Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline.” Practical radiation oncology (2025). PMID: 41317985 ↗
L1GUIDELINECited in: Indications by Stage - [16]
Ma X, Guo W, Sun J et al.. “Efficacy and safety of neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced esophagogastric junction or gastric cancer: a systematic review and meta analysis.” Frontiers in immunology (2026). PMID: 42292472 ↗
L1SR_MA_RCTCited in: Indications by Stage - [17]
Case A, Williams F, Prosser S et al.. “Reconsidering the Role of Radiotherapy for Inoperable Gastric Cancer: A Systematic Review of Gastric Radiotherapy Given With Definitive and Palliative Intent.” Clinical oncology (Royal College of Radiologists (Great Britain)) (2024). PMID: 39642760 ↗
L1SR_MA_RCTCited in: Indications by Stage, External Beam Radiotherapy (EBRT), Adjuvant and Palliative RT - [18]
Pera M, Gallego R, Montagut C et al.. “Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21652581 ↗
L4PHASE_1_TRIALCited in: Indications by Stage - [19]
Wang X, Yan O, Zhou J et al.. “Adjuvant Chemoradiotherapy or Chemotherapy After D2 Gastrectomy in Gastric Cancer: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42295761 ↗
L1RCTCited in: Indications by Stage - [20]
Liu X, Jin J, Zhou M et al.. “Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China.” Cancer communications (London, England) (2026). PMID: 41625476 ↗
L1RCTCited in: Indications by Stage - [21]
Qiao XX, Jiang HG, Tang Y et al.. “Long-Term Prognostic Analysis of Chemoradiation Therapy Versus Chemotherapy after D2 Resection for High-Risk Gastric Cancer: Results From a Prospective Randomized Control Study.” International journal of radiation oncology, biology, physics (2025). PMID: 40185210 ↗
L1RCTCited in: External Beam Radiotherapy (EBRT) - [22]
Chang JS, Koom WS, Lee Y et al.. “Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: is radiotherapy necessary after D2-dissection?” World journal of gastroenterology (2014). PMID: 25278687 ↗
L1RCTCited in: External Beam Radiotherapy (EBRT) - [23]
Zhu WG, Xua DF, Pu J et al.. “A randomized, controlled, multicenter study comparing intensity-modulated radiotherapy plus concurrent chemotherapy with chemotherapy alone in gastric cancer patients with D2 resection.” Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology (2012). PMID: 22985776 ↗
L1RCTCited in: External Beam Radiotherapy (EBRT) - [24]
Yu C, Yu R, Zhu W et al.. “Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery.” Journal of cancer research and clinical oncology (2011). PMID: 22105898 ↗
L1RCTCited in: External Beam Radiotherapy (EBRT) - [25]
Callister MD, Gunderson LL. “Advancements in radiation techniques for gastric cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2010). PMID: 20410335 ↗
L5OTHERCited in: External Beam Radiotherapy (EBRT) - [26]
Pasquier C, Créhange G, Vendrely V et al.. “Radiotherapy for cancers of the oesophagus, gastroesophageal junction, and stomach.” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2025). PMID: 41205452 ↗
L1GUIDELINECited in: External Beam Radiotherapy (EBRT) - [27]
Créhange G, Huguet F, Quero L et al.. “[Radiotherapy in cancers of the oesophagus, the gastric cardia and the stomach].” Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique (2016). PMID: 27523409 ↗
L1GUIDELINECited in: External Beam Radiotherapy (EBRT), Brachytherapy - [28]
Liu Y, Zhao G, Xu Y et al.. “Multicenter Phase 2 Study of Peri-Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer.” International journal of radiation oncology, biology, physics (2017). PMID: 28721893 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT) - [29]
Wang X, Shen Y, Zhu H et al.. “A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2015). PMID: 25609451 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT) - [30]
Badakhshi H, Gruen A, Graf R et al.. “Image-guided intensity-modulated radiotherapy for patients with locally advanced gastric cancer: a clinical feasibility study.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2013). PMID: 24122094 ↗
L4NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT) - [31]
Hu W, Ye J, Wang J et al.. “Incorporating breath holding and image guidance in the adjuvant gastric cancer radiotherapy: a dosimetric study.” Radiation oncology (London, England) (2012). PMID: 22716276 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT) - [32]
Alani S, Soyfer V, Strauss N et al.. “Limited advantages of intensity-modulated radiotherapy over 3D conformal radiation therapy in the adjuvant management of gastric cancer.” International journal of radiation oncology, biology, physics (2009). PMID: 19427558 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT) - [33]
Wang X, Li G, Zhang Y et al.. “Single-arc volumetric-modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: dosimetric comparisons with three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT).” Medical dosimetry : official journal of the American Association of Medical Dosimetrists (2013). PMID: 23791504 ↗
L1RCTCited in: External Beam Radiotherapy (EBRT) - [34]
Haneder S, Budjan JM, Schoenberg SO et al.. “Dose-dependent changes in renal (1)H-/(23)Na MRI after adjuvant radiochemotherapy for gastric cancer.” Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2014). PMID: 25445156 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT) - [35]
Boda-Heggemann J, Weiss C, Schneider V et al.. “Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer.” Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] (2013). PMID: 23558673 ↗
L2NON_RANDOMIZED_TRIALCited in: External Beam Radiotherapy (EBRT) - [36]
Ren F, Li S, Zhang Y et al.. “Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis.” Radiation oncology (London, England) (2019). PMID: 31118042 ↗
L2SR_COHORTCited in: External Beam Radiotherapy (EBRT) - [37]
Wang X, Zhao DB, Yang L et al.. “S-1 chemotherapy and intensity-modulated radiotherapy after D1/D2 lymph node dissection in patients with node-positive gastric cancer: a phase I/II study.” British journal of cancer (2017). PMID: 29235569 ↗
L4PHASE_1_TRIALCited in: External Beam Radiotherapy (EBRT) - [38]
Qiu M, Peng XC, Bi F et al.. “Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer.” Medical oncology (Northwood, London, England) (2015). PMID: 26025485 ↗
L4PHASE_1_TRIALCited in: External Beam Radiotherapy (EBRT) - [39]
Wang X, Jin J, Li YX et al.. “Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.” World journal of gastroenterology (2014). PMID: 24574780 ↗
L4PHASE_1_TRIALCited in: External Beam Radiotherapy (EBRT) - [40]
Liu D, Ma X, Xiao D et al.. “Efficacy and safety of targeting VEGFR drugs in treatment for advanced or metastatic gastric cancer: a systemic review and meta-analysis.” Oncotarget (2017). PMID: 29487720 ↗
L2SR_COHORTCited in: Brachytherapy - [41]
Di Vita M, Cappellani A, Piccolo G et al.. “The role of HIPEC in the treatment of peritoneal carcinomatosis from gastric cancer: between lights and shadows.” Anti-cancer drugs (2015). PMID: 25406023 ↗
L1SR_MA_RCTCited in: Brachytherapy - [42]
Wang J, Xiong J, Wang P et al.. “Analysis of the safety and efficacy of the self-pulling and latter transected technique in modified overlap anastomosis in total laparoscopic total gastrectomy.” Frontiers in oncology (2024). PMID: 38854721 ↗
L4COHORTCited in: Brachytherapy - [43]
Omari J, Drewes R, Orthmer M et al.. “Treatment of metastatic gastric adenocarcinoma with image-guided high-dose rate, interstitial brachytherapy as second-line or salvage therapy.” Diagnostic and interventional radiology (Ankara, Turkey) (2019). PMID: 31348004 ↗
L4COHORTCited in: Brachytherapy - [44]
Sugarbaker PH. “Laboratory and clinical basis for hyperthermia as a component of intracavitary chemotherapy.” International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group (2007). PMID: 17701534 ↗
L2NON_RANDOMIZED_TRIALCited in: Brachytherapy - [45]
Turina M, Pavlik CM, Heinimann K et al.. “Recurrent desmoids determine outcome in patients with Gardner syndrome: a cohort study of three generations of an APC mutation-positive family across 30 years.” International journal of colorectal disease (2012). PMID: 23114473 ↗
L2NON_RANDOMIZED_TRIALCited in: Brachytherapy - [46]
Halpern AL, McCarter MD. “Palliative Management of Gastric and Esophageal Cancer.” The Surgical clinics of North America (2019). PMID: 31047042 ↗
L5NARRATIVE_REVIEWCited in: Brachytherapy - [47]
Shi L, Wu C, Wu J et al.. “Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer.” Radiation oncology (London, England) (2012). PMID: 22827960 ↗
L5OTHERCited in: Brachytherapy - [48]
Zhang WF, Jin WD, Li B et al.. “Effect of brachytherapy on NF-κB and VEGF in gastric carcinoma xenografts.” Oncology reports (2014). PMID: 24926530 ↗
L5OTHERCited in: Brachytherapy - [49]
Zhang Y, Chung Y. “Nonparametric estimation of linear personalized diagnostics rules via efficient grid algorithm.” Statistics in medicine (2024). PMID: 38287456 ↗
L5OTHERCited in: Brachytherapy - [50]
Virgilio E, Ceci D, Cavallini M. “Surgical Endoscopic Vacuum-assisted Closure Therapy (EVAC) in Treating Anastomotic Leakages After Major Resective Surgery of Esophageal and Gastric Cancer.” Anticancer research (2018). PMID: 30275175 ↗
L4CASE_SERIESCited in: Brachytherapy - [51]
Chau I, Norman AR, Cunningham D et al.. “The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19164454 ↗
L1SR_MA_RCTCited in: Concurrent Chemoradiation, Outcomes - [52]
Grenader T, Waddell T, Peckitt C et al.. “Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2016). PMID: 26787231 ↗
L1RCTCited in: Concurrent Chemoradiation - [53]
Yamada Y, Higuchi K, Nishikawa K et al.. “Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 25316259 ↗
L1RCTCited in: Concurrent Chemoradiation - [54]
Ajani JA, Abramov M, Bondarenko I et al.. “A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28911091 ↗
L1RCTCited in: Concurrent Chemoradiation - [55]
Fazio N, Biffi R, Maibach R et al.. “Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26712905 ↗
L1RCTCited in: Concurrent Chemoradiation - [56]
Kanagavel D, Pokataev IA, Fedyanin MY et al.. “A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.” Annals of oncology : official journal of the European Society for Medical Oncology (2010). PMID: 20150573 ↗
L1RCTCited in: Concurrent Chemoradiation - [57]
Ryu MH, Baba E, Lee KH et al.. “Comparison of two different S-1 plus cisplatin dosing schedules as first-line chemotherapy for metastatic and/or recurrent gastric cancer: a multicenter, randomized phase III trial (SOS).” Annals of oncology : official journal of the European Society for Medical Oncology (2015). PMID: 26216386 ↗
L1RCTCited in: Concurrent Chemoradiation - [58]
Okines AF, Thompson LC, Cunningham D et al.. “Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2012). PMID: 23233651 ↗
L1RCTCited in: Concurrent Chemoradiation - [59]
Bajetta E, Floriani I, Di Bartolomeo M et al.. “Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2014). PMID: 24728035 ↗
L1RCTCited in: Concurrent Chemoradiation - [60]
Ishigami H, Fujiwara Y, Fukushima R et al.. “Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2018). PMID: 29746229 ↗
L1RCTCited in: Concurrent Chemoradiation - [61]
Ohtsu A, Shah MA, Van Cutsem E et al.. “Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2011). PMID: 21844504 ↗
L1RCTCited in: Concurrent Chemoradiation - [62]
Aoyama T, Nishikawa K, Fujitani K et al.. “Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2017). PMID: 28486692 ↗
L2RCT_PHASE2Cited in: Concurrent Chemoradiation - [63]
Shah MA, Janjigian YY, Stoller R et al.. “Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2015). PMID: 26438119 ↗
L2RCT_PHASE2Cited in: Concurrent Chemoradiation - [64]
Shitara K, Bang YJ, Wyrwicz LS et al.. “Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma.” ESMO open (2026). PMID: 41747585 ↗
L1RCTCited in: Concurrent Chemoradiation - [65]
Fujitani K, Yang HK, Mizusawa J et al.. “Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.” The Lancet. Oncology (2016). PMID: 26822397 ↗
L1RCTCited in: Concurrent Chemoradiation - [66]
Rosati G, Bilancia D, Germano D et al.. “Reduced dose intensity of docetaxel plus capecitabine as second-line palliative chemotherapy in patients with metastatic gastric cancer: a phase II study.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591806 ↗
L2NON_RANDOMIZED_TRIALCited in: Adjuvant and Palliative RT - [67]
Ly QP, Sasson AR. “Modern surgical considerations for gastric cancer.” Journal of the National Comprehensive Cancer Network : JNCCN (2008). PMID: 18926098 ↗
L5NARRATIVE_REVIEWCited in: Adjuvant and Palliative RT - [68]
Datta J, McMillan MT, Shang EK et al.. “Omission of adjuvant therapy after gastric cancer resection: development of a validated risk model.” Journal of the National Comprehensive Cancer Network : JNCCN (2015). PMID: 25964639 ↗
L5OTHERCited in: Adjuvant and Palliative RT - [69]
Dikken JL, Jansen EP, Cats A et al.. “Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2010). PMID: 20368551 ↗
L4PHASE_1_TRIALCited in: Adjuvant and Palliative RT - [70]
Ghiglieri C, Dempster M, Wright S et al.. “Psychosocial functioning in individuals with advanced oesophago-gastric cancer: a mixed methods systematic review.” BMC palliative care (2023). PMID: 37891568 ↗
L2SR_COHORTCited in: Adjuvant and Palliative RT - [71]
Hong J, Chen Y, Li J et al.. “Comparison of gastrojejunostomy to endoscopic stenting for gastric outlet obstruction: An updated Systematic Review and Meta-analysis.” American journal of surgery (2021). PMID: 34728070 ↗
L2SR_COHORTCited in: Adjuvant and Palliative RT - [72]
Guchelaar NAD, Nasserinejad K, Mostert B et al.. “Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: a systematic review and meta-analysis.” The British journal of surgery (2024). PMID: 38722803 ↗
L1SR_MA_RCTCited in: Adjuvant and Palliative RT - [73]
Wang Z, Dong L, Shi W et al.. “Postoperative therapy for local-advanced gastric cancer: A systematic review and meta-analysis.” Advances in clinical and experimental medicine : official organ Wroclaw Medical University (2024). PMID: 38085005 ↗
L1SR_MA_RCTCited in: Adjuvant and Palliative RT - [74]
Orditura M, Martinelli E, Galizia G et al.. “Chemoradiotherapy as adjuvant treatment of gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2007). PMID: 17591807 ↗
L5NARRATIVE_REVIEWCited in: Adjuvant and Palliative RT - [75]
Luo D, Xu H, Jiang C et al.. “The prognostic role of palliative gastrectomy in advanced gastric cancer: a systematic review and meta-analysis.” BMC cancer (2024). PMID: 39227821 ↗
L2SR_COHORTCited in: Adjuvant and Palliative RT - [76]
Kopecky K, Monton O, Rosman L et al.. “Palliative interventions for patients with advanced gastric cancer: a systematic review.” Chinese clinical oncology (2022). PMID: 36632980 ↗
L2SR_COHORTCited in: Adjuvant and Palliative RT - [77]
Meyer HJ, Wienke A, Surov A. “Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis.” Nutrition and cancer (2022). PMID: 35603926 ↗
L2SR_COHORTCited in: Adjuvant and Palliative RT - [78]
Lee J, Lee J, Tripathi R et al.. “Sociodemographic Disparities and Impact of Palliative Care Utilization During End-of-Life Hospitalizations in Patients with Gastric Cancer.” Journal of palliative medicine (2025). PMID: 41466501 ↗
L3RETROSPECTIVE_COHORTCited in: Adjuvant and Palliative RT - [79]
Kim WJ, Choi CW, Kim SJ et al.. “Predictors of clinical failure after stenting for malignant esophageal stricture: a single-institution retrospective analysis.” Surgical endoscopy (2025). PMID: 40835762 ↗
L3COHORTCited in: Adjuvant and Palliative RT - [80]
Kitti P, Anttonen A, Nuutinen M et al.. “Specialist palliative care is associated with reduced healthcare utilization in patients with advanced esophageal and gastric cancer: a nationwide register-based study.” Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2025). PMID: 40471285 ↗
L3RETROSPECTIVE_COHORTCited in: Adjuvant and Palliative RT - [81]
Jiang W, Wang H, Zhang X et al.. “Patterns of Recurrence After D2 Radical Surgery for Gastric Cancer: Implications for Postoperative Radiation Therapy.” Practical radiation oncology (2025). PMID: 40113039 ↗
L3COHORTCited in: Adjuvant and Palliative RT - [82]
Kim JW, Choi JY, Park W et al.. “Pilot Study for Feasibility of Onco-Geriatric Intervention Model in Older Patients with Cancer in a Tertiary Academic Hospital.” Cancer research and treatment (2025). PMID: 40083083 ↗
L4COHORTCited in: Adjuvant and Palliative RT - [83]
Santoni M, Guerra F, Conti A et al.. “Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies.” Cancer treatment reviews (2017). PMID: 28818671 ↗
L2SR_COHORTCited in: Acute and Late Toxicity - [84]
Sasako M, Sano T, Yamamoto S et al.. “D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.” The New England journal of medicine (2008). PMID: 18669424 ↗
L1RCTCited in: Acute and Late Toxicity - [85]
Wang X, Zhang H, Xue Y et al.. “Comparing safety and short-term outcomes of proximal gastrectomy with double-flap technique and other reconstructions for proximal gastric cancer: a systematic review and meta-analysis.” BMC surgery (2026). PMID: 41580732 ↗
L1SR_MA_RCTCited in: Acute and Late Toxicity - [86]
Chen J, Wang F, Wang Y et al.. “A comparison of postoperative outcomes between robotic-assisted and laparoscopic-assisted total gastrectomy: a comprehensive meta-analysis and systematic review.” BMC surgery (2025). PMID: 40375289 ↗
L1SR_MA_RCTCited in: Acute and Late Toxicity - [87]
Zhu G, Jiao X, Zhou S et al.. “Can proximal gastrectomy with double-tract reconstruction replace total gastrectomy? a meta-analysis of randomized controlled trials and propensity score-matched studies.” BMC gastroenterology (2024). PMID: 39044132 ↗
L1SR_MA_RCTCited in: Acute and Late Toxicity - [88]
Menegat BLRS, Menegat ALRS, Dantas CR et al.. “Safety and feasibility of subtotal gastrectomy compared with completion total gastrectomy for remnant gastric cancer: A systematic review and meta-analysis.” Surgical oncology (2026). PMID: 42248045 ↗
L4SR_COHORTCited in: Acute and Late Toxicity - [89]
Miki Y, Bito T, Makuuchi R et al.. “Limited lymphadenectomy for elderly patient with gastric cancer: a systematic review and meta-analysis.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 41879959 ↗
L2SR_COHORTCited in: Acute and Late Toxicity - [90]
Chen M, Peng J, Lai H et al.. “Treatment of Gastric Cancer: Laparoscopic Pylorus-Preserving Gastrectomy or Laparoscopic Distal Gastrectomy? A Systematic Review and Meta-Analysis.” Journal of surgical oncology (2025). PMID: 41472564 ↗
L2SR_COHORTCited in: Acute and Late Toxicity - [91]
Zizzo M, Morini A, Zanelli M et al.. “Impact of Duodenal Stump Reinforcement in Preventing Duodenal Stump Fistula/Leakage After Distal or Total Gastrectomy for Malignant Disease: A Meta-Analysis of Comparative Studies.” Cancers (2025). PMID: 40507217 ↗
L2SR_COHORTCited in: Acute and Late Toxicity - [92]
Zaman S, Hussain MI, Kausar M et al.. “Intracorporeal versus extracorporeal anastomosis in laparoscopic total gastrectomy: a systematic review and meta-analysis.” International journal of surgery (London, England) (2025). PMID: 40009559 ↗
L2SR_COHORTCited in: Acute and Late Toxicity - [93]
Menegat ALRS, Menegat BLRS, Simões BCG et al.. “Comparative Outcomes of Spleen Preservation and Splenectomy in Total Gastrectomy for Proximal Gastric Cancer: A Systematic Review and Meta-Analysis.” Journal of gastrointestinal cancer (2025). PMID: 41091291 ↗
L1SR_MA_RCTCited in: Acute and Late Toxicity - [94]
Matsumoto Y, Terashima M, Fujiya K et al.. “Association between the inflow pattern of the left gastric vein and postoperative pancreatic fistula after laparoscopic gastrectomy.” Surgical endoscopy (2026). PMID: 42265294 ↗
L4COHORTCited in: Acute and Late Toxicity - [95]
Fujita S, Harada H, Okuno K et al.. “Pancreas-contactless open gastrectomy for gastric cancer and postoperative pancreatic complications: A retrospective cohort study.” Surgical oncology (2026). PMID: 42250430 ↗
L3RETROSPECTIVE_COHORTCited in: Acute and Late Toxicity - [96]
Takahashi K, Fujiya K, Terashima M et al.. “Comparison of long-term outcomes of robotic gastrectomy and laparoscopic gastrectomy using the modified age-adjusted Charlson Comorbidity Index.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2026). PMID: 42113328 ↗
L3COHORTCited in: Acute and Late Toxicity - [97]
Filip B, Grigoraș A, Scripcariu DV et al.. “Neoadjuvant Treatment Versus Upfront Surgery in Gastric Cancer Patients: Early Postoperative and Pathological Results: A Retrospective Study in a Tertiary Center.” Journal of clinical medicine (2026). PMID: 41899266 ↗
L4COHORTCited in: Acute and Late Toxicity - [98]
Tokuhara T, Nakata E, Kawai I et al.. “Reframing gastric lymph nodes as a parapancreatic lymph chain: an embryology-driven rationale for omento-bursectomy and omentum-preserving gastrectomy to facilitate safe infrapyloric lymph node dissection.” World journal of surgical oncology (2025). PMID: 41470024 ↗
L3RETROSPECTIVE_COHORTCited in: Acute and Late Toxicity - [99]
Ri M, Nunobe S, Narita T et al.. “Time-sequential prediction of postoperative complications after gastric cancer surgery using machine learning: a multicenter cohort study.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2025). PMID: 40921854 ↗
L3COHORTCited in: Acute and Late Toxicity - [100]
Yamaguchi T, Kadoya S, Ishibayashi K et al.. “Asthma is a risk factor for postoperative pulmonary complications and intra-abdominal infectious complications after gastrectomy.” Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract (2025). PMID: 40744154 ↗
L3COHORTCited in: Acute and Late Toxicity - [101]
Huang J, Dong Z, Chen F et al.. “Risk analysis of jejunal orientation on the incidence of dysphagia after total gastrectomy: a retrospective cohort study.” Surgical endoscopy (2025). PMID: 40116901 ↗
L4RETROSPECTIVE_COHORTCited in: Acute and Late Toxicity - [102]
Ushimaru Y, Omori T, Yamamoto K et al.. “Robotic and laparoscopic gastrectomy for gastric cancer: comparative insights into perioperative performance and three-year survival outcomes.” Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (2025). PMID: 40009253 ↗
L3RETROSPECTIVE_COHORTCited in: Acute and Late Toxicity - [103]
Nitti D, Wils J, Dos Santos JG et al.. “Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.” Annals of oncology : official journal of the European Society for Medical Oncology (2005). PMID: 16293676 ↗
L1SR_MA_RCTCited in: Outcomes - [104]
Sada YH, Smaglo BG, Tan JC et al.. “Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma.” Journal of the National Comprehensive Cancer Network : JNCCN (2019). PMID: 30787129 ↗
L3RETROSPECTIVE_COHORTCited in: Outcomes - [105]
Singh PP, Singh S. “Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis.” Annals of oncology : official journal of the European Society for Medical Oncology (2013). PMID: 23599253 ↗
L2SR_COHORTCited in: Outcomes - [106]
Okines AFC, Norman AR, McCloud P et al.. “Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer.” Annals of oncology : official journal of the European Society for Medical Oncology (2009). PMID: 19474114 ↗
L2SR_COHORTCited in: Outcomes - [107]
Cassidy J, Saltz L, Twelves C et al.. “Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients.” Annals of oncology : official journal of the European Society for Medical Oncology (2011). PMID: 21415237 ↗
L2SR_COHORTCited in: Outcomes - [108]
Pietrantonio F, Randon G, Di Bartolomeo M et al.. “Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials.” ESMO open (2021). PMID: 33460964 ↗
L1SR_MA_RCTCited in: Outcomes - [109]
Janjigian YY, Shitara K, Ajani JA et al.. “Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41687718 ↗
L1RCTCited in: Outcomes - [110]
Park SH, Lim DH, Sohn TS et al.. “A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial☆.” Annals of oncology : official journal of the European Society for Medical Oncology (2020). PMID: 33278599 ↗
L1RCTCited in: Outcomes - [111]
Liu R, Zhao J, Zhang R et al.. “Anbenitamab in previously treated HER2-positive gastric cancer (KC-WISE): prespecified interim analysis of a randomized, phase III clinical trial.” Annals of oncology : official journal of the European Society for Medical Oncology (2026). PMID: 41571045 ↗
L1RCTCited in: Outcomes - [112]
Wang X, Jiang Y, Yang S et al.. “Foundation Model for Predicting Prognosis and Adjuvant Therapy Benefit From Digital Pathology in GI Cancers.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40168636 ↗
L2PROSPECTIVE_COHORTCited in: Outcomes - [113]
Shen L, Shan YS, Hu HM et al.. “Management of gastric cancer in Asia: resource-stratified guidelines.” The Lancet. Oncology (2013). PMID: 24176572 ↗
L1GUIDELINECited in: Outcomes - [114]
Kang YK, Yook JH, Park YK et al.. “PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34133211 ↗
L1RCTCited in: Outcomes - [115]
Sakai D, Kadowaki S, Kawabata R et al.. “Randomized Phase III Trial of Ramucirumab Beyond Progression Plus Irinotecan in Patients With Ramucirumab-Refractory Advanced Gastric Cancer: RINDBeRG Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2025). PMID: 40408613 ↗
L1RCTCited in: Outcomes - [116]
Li C, Tian Y, Zheng Y et al.. “Pathologic Response of Phase III Study: Perioperative Camrelizumab Plus Rivoceranib and Chemotherapy Versus Chemotherapy for Locally Advanced Gastric Cancer (DRAGON IV/CAP 05).” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024). PMID: 39383487 ↗
L1RCTCited in: Outcomes - [117]
van der Veen A, Brenkman HJF, Seesing MFJ et al.. “Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021). PMID: 34581617 ↗
L1RCTCited in: Outcomes - [118]
Li J, Qin S, Xu J et al.. “Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26884585 ↗
L1RCTCited in: Outcomes - [119]
Lee CK, Kim HS, Jung M et al.. “Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023). PMID: 37883723 ↗
L1RCTCited in: Outcomes - [120]
Hu Y, Huang C, Sun Y et al.. “Morbidity and Mortality of Laparoscopic Versus Open D2 Distal Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2016). PMID: 26903580 ↗
L1RCTCited in: Outcomes